NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. CRWV

Go back to NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains

NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit

April 27, 2016 8:53 AM EDT

NeoGenomics (NASDAQ: NEO) reported Q1 EPS of $0.03, $0.10 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $59.7 million versus the consensus estimate of $57 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.08-$0.13, versus the consensus of ($0.22). NeoGenomics sees... More